Prevention and treatment of bone metastases

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 2998-3006

  Woodward, E J ^a,b   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Bisphosphonates; Bone; Breast cancer; Metastasis

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GOSERELIN; IBANDRONIC ACID; LETROZOLE; LEUPRORELIN; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE LESION; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER SURVIVAL; CELL MIGRATION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG FEVER; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; JAW OSTEONECROSIS; MORBIDITY; MULTIPLE CYCLE TREATMENT; MYALGIA; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; SPINAL CORD; SPINAL CORD COMPRESSION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 78649883378     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563581     Document Type: Article

References (84)

1. Coleman RE. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. Clin Cancer Res 2006; 12(20): 6243s-9s.
2. McCrea LE, Karafin L. Carcinoma of the prostate: metastases, therapy and survival; a statistical analysis of five hundred cases. J Int Coll Surg 1958; 29(6): 723-8.
3. Käkönen S-M, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003; 97(S3): 834-9.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2(8): 584-93.
5. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 2008; 68(14): 5785-94.
6. [6] Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular Mechanisms of Action of Bisphosphonates: Current Status. Clin Cancer Res 2006; 12(20): 6222s-30s.
7. Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006; 147(4): 437-45.
8. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111(3): 306-12.
9. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998; 100(2): 317-25.
10. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000; 88(5): 1082-90.
11. Carteni G, Bordonaro R, Giotta F, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 2006; 11(7): 841-8.
12. Chow E, Hird A, Velikova G, et al. The european organisation for research and treatment of cancer quality of life questionnaire for patients with bone metastases: The EORTC QLQ-BM22. Eur J Cancer 2009; 45(7): 1146-52.
13. Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008; 16(8): 879-89.
14. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97(1): 59-69.
15. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links Ntelopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20(3): 850-6.
16. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113(1): 193-201.
17. Body J-J, Lichinitser M, Tjulandin S, Garnero P, Bergström B. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 2007; 18(7): 1165-71.
18. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23(22): 4925-35.
19. Lester JE, Brown JE, Hannon RA, et al. The use of a point of care device for monitoring the bone resorption biomarker urinary Ntelopeptide in cancer patients with bone metastases. Bone 2010; 46(3): 801-5.
20. [20] UKCRN. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=1737. [2/3/2010].
21. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer. 2008; 98(11): 1736-40.
22. Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006; 17(7): 1072-82.
23. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006; 24(30): 4895-900.
24. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the american society for bone and mineral research. J Bone Mineral Res 2007; 22(10): 1479-91.
25. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98(3): 698-705.
26. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94(1): 164-70.
27. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60(11): 2949-54.
28. Sawada K, Morishige KI, Tahara M, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2002; 62(21): 6015-20.
29. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003; 88(10): 1631-40.
30. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58(23): 5294-7.
31. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84(8): 1126-34.
32. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61(6): 2602-8.
33. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001; 84(7): 951-8.
34. Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer 2002; 87(3): 366-71.
35. Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the thirdgeneration bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005; 47(1): 31-9.
36. Ozturk OH, Bozcuk H, Burgucu D, et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 2007; 31(9): 1069-71.
37. Tassone P, Tagliaferri P, Viscomi C, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003; 88(12): 1971-8.
38. Sewing L, Steinberg F, Schmidt H, Goke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008; 13(6): 782-9.
39. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82(8): 1459-68.
40. Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010; 102(6): 1010-7.
41. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27(2): 92-103.
42. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113(3): 364-71.
43. [43] Brown HK, Ottewell PD, Coleman RE, Holen I. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med 2009; [Epub ahead of print].
44. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302(3): 1055-61.
45. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96(2): 384-92.
46. [46] Guaitani A, Polentarutti N, Filippeschi S, et al. Effects of disodium etidronate in murine tumor models. Eur J Cancer Clin Oncol 1984; 20(5): 685-9, 91-93.
47. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88(S12): 2979-88.
48. Hiraga T, Ueda A, Tamura D, et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 2003; 106(6): 973-9.
49. Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005; 104(8): 1713-20.
50. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100(16): 1167-78.
51. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010; 126(2): 522-32.
52. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-a long-term follow-up. Ann Oncol 2008; 19(12): 2007-11.
53. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19(1): 10-7.
54. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007; 96(12): 1796-801.
55. Kokufu I, Kohno N, Takao S, et al. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes. Proc Am Soc J Clin Oncol 2004; 22(14_suppl): 530.
56. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008; 47(4): 740-6.
57. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360(7): 679-91.
58. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. Cancer 2008; 112(5): 1001-10.
59. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25(7): 829-36.
60. Schenk N, Lombart A, Frassoladti A, et al 2008 POSTER The EZO- FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let). Eur J Cancer Suppl 2007; 5(4): 186-7.
61. Coleman RTH, Cameron D, Bell R, et al. Eds. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-first safety data from the AZURE trial (BIG01/04). San Antonio Breast Cancer Symposium 2006.
62. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010; 102(7): 1099-105.
63. Dearnaley DP, Mason MD, Parmar MKB, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009; 10(9): 872-6.
64. Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther 2009; 9(4): 465-79.
65. Fizazi K, Lipton A, Mariette X, Body JJ, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27(10): 1564-71.
66. Stopeck ADBR, Fujiwara Y, Lichinitser M, et al. Eds. A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases. SABCS 2009.
67. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11(1): 59-65.
68. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996; 14(9): 2552-9.
69. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16(6): 2038-44.
70. Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19(4C): 3383-92.
71. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17(3): 846-54.
72. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebocontrolled phase III studies. Br J Cancer 2004; 90(6): 1133-7.
73. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14(9): 1399-405.
74. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23(15): 3314-21.
75. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340(8827): 1049-52.
76. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16(2): 593-602.
77. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998; 100(2): 317-25.
78. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebocontrolled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21(23): 4277-84.
79. Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94(19): 1458-68.
80. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial--the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003; 21(16): 3150-7.
81. Coleman RE Bundred N, De Boer R, Llombart A, et al. editor. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. San Antonio Breast Cancer Symposium San Antonio, USA 2009.
82. Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA. Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma. Curr Pharm Des 2010; 16(11): 1272-83.
83. Holen I, Coleman RE. Bisphosphonates as Treatment of Bone Metastases. Curr Pharm Des 2010; 15(11): 1262-71.
84. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002; 8(21): 1929-44.